Serum and cerebrospinal fluid neurofilament light chain in patients with central nervous system infections caused by varicella-zoster virus by Tyrberg, Tobias et al.
Serum and cerebrospinal fluid neurofilament light chain in
patients with central nervous system infections caused by
varicella-zoster virus
Downloaded from: https://research.chalmers.se, 2021-08-31 11:03 UTC
Citation for the original published paper (version of record):
Tyrberg, T., Nilsson, S., Blennow, K. et al (2020)
Serum and cerebrospinal fluid neurofilament light chain in patients with central nervous system
infections caused by varicella-zoster virus
Journal of NeuroVirology, 26(5): 719-726
http://dx.doi.org/10.1007/s13365-020-00889-2
N.B. When citing this work, cite the original published paper.
research.chalmers.se offers the possibility of retrieving research publications produced at Chalmers University of Technology.
It covers all kind of research output: articles, dissertations, conference papers, reports etc. since 2004.
research.chalmers.se is administrated and maintained by Chalmers Library
(article starts on next page)
Serum and cerebrospinal fluid neurofilament light chain in patients
with central nervous system infections caused by varicella-zoster
virus
Tobias Tyrberg1 & Staffan Nilsson2 & Kaj Blennow3,4 & Henrik Zetterberg3,4,5,6 & Anna Grahn1
Received: 14 January 2020 /Revised: 14 January 2020 /Accepted: 29 July 2020
# The Author(s) 2020
Abstract
Varicella-zoster virus (VZV) is a common cause of viral central nervous system (CNS) infection, and patients may suffer from
severe neurological sequelae. The biomarker neurofilament light chain (NFL) is used for assessment of neuronal damage and is
normally measured in cerebrospinal fluid (CSF). Novel methods have given the possibility to measure NFL in serum instead,
which could be a convenient tool to estimate severity of disease and prognosis in VZV CNS infections. Here, we investigate the
correlation of serum and CSF NFL in patients with VZV CNS infection and the association of NFL levels in serum and CSFwith
different VZV CNS entities. NFL in serum and CSF was measured in 61 patients who were retrospectively identified with
neurological symptoms and VZVDNA in CSF detected by PCR. Thirty-three herpes zoster patients and 40 healthy blood donors
served as control groups. NFL levels in serum and CSF correlated strongly in the patients with VZV CNS infection. Encephalitis
was associated with significantly higher levels of NFL in both serum and CSF compared with meningitis and Ramsay Hunt
syndrome. Surprisingly, herpes zoster controls had very high serum NFL levels, comparable with those shown in encephalitis
patients. We show that analysis of serum NFL can be used instead of CSF NFL for estimation of neuronal injury in patients with
VZV CNS infection. However, high levels of serum NFL also in patients with herpes zoster, without signs of CNS involvement,
may complicate the interpretation.
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Introduction
Varicella-zoster virus (VZV) is a neurotropic virus in the her-
pes family, and it is one of the most common viral agents
causing infection in the central nervous system (CNS)
(Granerod et al. 2010; Mailles et al. 2012; Persson et al.
2009). After primary infection, the virus establishes latency
in sensory and autonomic ganglia. Reactivation can cause
several different clinical manifestations involving the CNS,
such as encephalitis, meningitis, myelitis, vasculitis, and cra-
nial nerve affection, including Ramsay Hunt syndrome with
peripheral facial palsy (Persson et al. 2009). Encephalitis is the
most serious manifestation and is associated with both high
mortality and morbidity (Mailles et al. 2012), but all VZV
CNS manifestations may include serious neurological sequels
(Persson et al. 2009). Diagnostic and prognostic tools are of
importance to try to estimate the degree of CNS injury caused
by the infection, and possibly also the need of rehabilitation.
Different biomarkers measured in cerebrospinal fluid (CSF) or
serum may be used for this purpose.
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In patients with VZV CNS infection, viral load and some
other biomarkers have been investigated, such as neurofila-
ment light chain (NFL), glial fibrillary acidic protein and
S-100B protein (Aberle et al. 2005; Grahn et al. 2013;
Lindstrom et al. 2016; Persson et al. 2009). Viral load of
VZV in CSF was in one study shown to be higher in enceph-
alitis patients (Aberle et al. 2005), but could in another study
not differ against meningitis patients and was not related to the
outcome (Persson et al. 2009). NFL is a protein exclusively
expressed in neurons and is used as a biomarker for
neuroaxonal damage (Gaetani et al. 2019). Increased concen-
trations of CSF NFL are seen in patients with a wide range of
neurodegenerative diseases (Lycke et al. 1998; Nylen et al.
2006; Nylen et al. 2002). CSF NFL concentrations have been
reported to be higher in patients with VZV CNS infection
compared with that of controls. This increase is most pro-
nounced in patients with encephalitis, but is also seen in those
with meningitis (Grahn et al. 2013) and Ramsay Hunt syn-
drome (Grahn et al. 2013; Lindstrom et al. 2016), and may be
a reflection of the degree of CNS injury.
However, most biomarkers used in the diagnostics of CNS
infections are based on analysis of CSF obtained through a
lumbar puncture, a sometimes harmful procedure for the pa-
tient. During recent years, a new method for analysis of bio-
markers in serum has been introduced. The novel ultra-
sensitive Single-molecule array (Simoa) method, which is a
digital enzyme-linked immunosorbent assay (ELISA) (Cohen
and Walt 2017), has been shown to be a both reliable and
compelling alternative for analysis of NFL in patients with
CNS disease (Gisslen et al. 2016). A strong correlation has
been found between concentrations of NFL in blood and CSF
in neurodegenerative diseases (Disanto et al. 2017; Gaiottino
et al. 2013) and HIV-related CNS injury (Gisslen et al. 2016).
Yet, the usefulness of measuring serumNFL concentrations in
patients with viral CNS infections is scarcely elucidated, and
no studies have so far evaluated this method in patients with
VZV CNS infection.
Our aim was to study the correlation between serum and
CSFNFL concentrations in patients with VZVCNS infection,




CSF samples with VZV DNA-positive by PCR were identi-
fied between 2007 and 2014 at the Department of Virology at
Sahlgrenska University Hospital in Gothenburg, Sweden. The
samples had been drawn in the clinical setting due to CNS
symptoms from patients admitted to the Sahlgrenska
University Hospital. For comparison, paired CSF and serum
samples were identified, i.e. serum taken within 2 days of CSF
sample. Clinical information was obtained through medical
records. Patients with detectable VZV DNA in CSF and
symptoms suggestive of CNS involvement were considered
to have a VZV CNS infection. The patients were categorised
based on clinical symptoms and criteria published earlier
(Grahn et al. 2013) into either encephalitis, meningitis or
RamsayHunt syndrome. Patients who did not meet the criteria
for any of these groups were categorised as “other neurolog-
ical symptoms”. Exclusion criteria were lack of consent and
other concomitant CNS disease.
Two control groups were defined. One group of 33 pa-
tients, who had been admitted for herpes zoster without
CNS symptoms to Sahlgrenska University Hospital between
2000 and 2013, was identified through a diagnosis registry.
The inclusion criteria were herpes zoster without CNS mani-
festations and at least one serum sample available for analysis.
The serum samples were drawn a median 4 days (range − 11–
53) in relation to onset of disease. Thirty-one out of the 33
patients were sampled within − 2–15 days in relation to onset
of disease. The second control group consisted of 40 healthy
blood donors.
The study was approved by the medical ethics committee at
Gothenburg University, and informed consent was obtained
for inclusion in the study.
Management of serum and CSF samples
Samples of CSF drawn at the acute stage of disease
were analysed for VZV DNA with an in-house
TaqMan PCR for quantitative analysis of viral load
(Persson et al. 2009). The CSF and serum samples were
stored at − 20 °C. In 2017, 48 of the CSF samples were
analysed for NFL using the NF-Light kit from
UmanDiagnostics, according to instructions by the kit
manufacturer (UmanDiagnostics, Umeå, Sweden). In
2018, 9 additional CSF samples (2 encephalitis, 2 men-
ingitis, 4 Ramsay Hunt syndrome, 1 “other neurological
symptoms”) were analysed for NFL using an in-house
method (Gaetani et al. 2018). As previously described
in detail (Gaetani et al. 2018), this method is highly
correlated with the UmanDiagnostics assay (r = 0.9984,
p < 0.001, no offset), which was verified in a Passing-
Bablok analysis. Serum NFL concentration was mea-
sured using an in-house digital ELISA on the Simoa
platform as previously described in detail (Gisslen
et al. 2016). Albumin ratio was calculated as a measure
of blood-brain barrier damage (CSF albumin (mg/L)/se-
rum albumin (g/L)). When comparing CSF NFL levels
between patient groups, we performed an age adjust-
ment of CSF NFL based on the formula (CSF NFL
(pg/mL) = 97.5 × 1.031age) (Yilmaz et al. 2017).
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Statistical analysis
Serum and CSF NFL concentrations were log-transformed
prior to analysis to obtain a normal distribution. NFL concen-
trations are presented as median and interquartile range (IQR)
or geometric mean and 95% confidence interval. Comparison
of raw NFL concentrations in CSF and serum as well as age-
adjusted CSF NFL (Yilmaz et al. 2017) was made using one-
way ANOVA with Tukey’s multiple comparison test.
ANCOVA was used to adjust for group differences in serum
and CSF NFL correlation, and to adjust for age when compar-
ing serum NFL levels. Pearson correlation analysis was used
for correlations. Prism version 7.0d (GraphPad Software Inc.,
La Jolla, CA), SPSS version 25 (IBM, Armonk, NY) and R
version 3.3.1 were used for statistical calculations.
Results
Patients and controls
Sixty-one consenting patients with detectable VZV DNA in
CSF and neurological symptoms related to VZV infection
were included in the study. Nine of the included patients were
only analysed for either serum NFL or CSF NFL due to in-
sufficient sample volumes (serumNFL only (n = 4), CSFNFL
only (n = 5)). Both serum and CSF samples were drawn a
median 4 days (range 0–90) after onset of disease. The patient
who was sampled 90 days after onset of symptoms was a 38-
year-old man who presented with slowly progressive bilateral
proximal weakness in arms and legs for the last 3 months.
After treatment with acyclovir and cortisone, the symptoms
slowly regressed. Details about the study groups and compar-
ison of clinical data are shown in Table 1. Notably, the pa-
tients with encephalitis in our material were significantly older
than patients with meningitis and herpes zoster, and the
healthy controls (p < 0.01 for all).
Seven patients who did not meet the criteria for any
predefined group were categorised as “other neurological
symptoms” which consisted of the following diagnoses: en-
cephalopathy (n = 4), polyneuropathy (n = 1), radiculitis (n =
1) and cranial nerve ganglionitis (n = 1). Two patients with
peripheral facial palsy that also reached criteria for meningitis
were categorised as Ramsay Hunt syndrome. One patient with
encephalitis presented with subarachnoid haemorrhage due to
an aneurysm which was regarded as a VZV manifestation.
Eleven of the patients with VZV CNS infection were immu-
nocompromised (vasculitis (n = 3), systemic lupus erythemato-
sus (n = 2), leukaemia (n= 2), essential thrombocytosis (n = 1),
lungmalignancy (n= 1), rheumatoid arthritis (n= 1) andCrohn’s
disease (n = 1)). Of the herpes zoster controls, 17 patients were
immunocompromised (leukaemia (n = 6), lymphoma (n = 3),
HIV (n = 3), rheumatoid arthritis (n= 1), Wilm’s tumour (n =
1), liver transplant (n = 1), kidney transplant (n = 1) and ulcera-
tive colitis (n = 1)). All of these patients received
immunosuppressing treatment except for six patients in the her-
pes zoster control group (HIV (n = 3), chronic lymphocytic leu-
kaemia (n = 2), and lymphocytic lymphoma (n = 1)).
NFL in serum and CSF
There was a strong correlation between concentrations of NFL
in serum and CSF in the patients with VZV CNS infection
(r = 0.72, p < 0.001) (Fig. 1). To evaluate if the correlation
varied between subgroups, an interaction term between sub-
group and CSF NFL was put into the model. The interaction
term was not significant, and therefore, we could assume par-
allel regression lines. In this model, the serum/CSF NFL ratio
was significantly different between the encephalitis and men-
ingitis patients (Fig. 1). Every given CSFNFL level correlated
Table 1 Clinical data of patients with different manifestations of VZV CNS infection (n = 61) and controls (n = 73)








n 17 28 9 7 33 40
Age, median (range) 73 (34–89) 32.5 (15–82) 57 (20–82) 47 (22–84) 41 (3–85) 54.5 (18–75)







1300 (50–759,000) 1150 (100–11,000) ND ND
Albumin ratio,
median (range)
24.2 (4.9–156.7) 19.2 (3.3–39.3) 11.3 (2.8–25) 12.1(5.6–19.3) ND ND
Immunocompromised,
n (%)
4 (24) 5 (18) 0 2 (29) 17 (52) ND
Rash, n (%) 7 (41) 12 (43) 7 (78) 5 (71) 33 (100) ND
CSF cerebrospinal fluid, VZV varicella-zoster virus
a One sample with CSF VZV = 0 was drawn 25 days after onset of symptoms, and 21 days after the first CSF sample that was VZV DNA-positive by
PCR
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to a mean 4.9 times higher serum NFL level in encephalitis
patients than in patients with meningitis (95% confidence in-
terval 1.4–16.6, p = 0.005). The patients with “other neurolog-
ical symptoms” were not analysed separately as only four
patients had available paired samples.
Serum
The herpes zoster controls had higher serum NFL concentra-
tions than the VZV CNS infection group as a whole (median
57.3 pg/mL; IQR 17.2–124.5 versus 25.5 pg/mL; 7.3–127.1,
p = 0.043) (Fig. 2). After subdividing the patients, the enceph-
alitis patients had significantly higher concentrations of serum
NFL than those with meningitis (155.6 pg/mL; 65.1–
403.8 pg/mL versus 8.1 pg/mL; 3.5–21.3 pg/mL, p < 0.001),
Ramsay Hunt syndrome (30.4 pg/mL; 7.4–114.4 pg/mL, p =
0.043), and the healthy controls (9 pg/mL; 5.9–14.7 pg/mL,
p < 0.001) (Fig. 2b). The herpes zoster controls presented
significantly higher concentrations of serum NFL compared
with the meningitis patients (p < 0.001) and healthy controls
(p < 0.001), but not compared with the encephalitis patients
(p = 0.22).
No age-related cutoffs have been established for serum
NFL. To adjust for age differences between the study groups
in our material, we performed an analysis of covariance with
age as a covariate variable and an interaction term between
age and group. Since the interaction was not significant, we
dropped the interaction term and assumed parallel regression
lines (Fig. 3). For comparison, serum NFL concentration
across all groups were adjusted to the approximate mean age =
50. The resulting adjusted serum NFL concentrations were as
follows (geometric means and 95% confidence intervals are
presented): encephalitis 79.4 pg/mL (CI 44.4–141.9), menin-
gitis 10.3 pg/mL (CI 6.5–16.5), Ramsay Hunt syndrome
27.4 pg/mL (CI 12.9–58.1), “other neurological symptoms”
34.8 pg/mL (CI 13.9–87.3), herpes zoster controls 74.1 pg/mL
(CI 49.7–110.4), and healthy controls 9.5 pg/mL (CI 6.6–
13.6). p values for group comparisons are shown in Table 2.
CSF
The concentrations of NFL in CSF were significantly higher
in the encephalitis patients (median 2671 pg/mL; IQR 1742–
5161 pg/mL) compared with the patients with meningitis
(510.9 pg/mL; 255.4–688.6 pg/mL, p < 0.001) and Ramsay
Hunt syndrome (748 pg/mL; 288.2–1401 pg/mL, p = 0.013),
but not compared with the patients with “other neurological
symptoms” (616.7 pg/mL; 218.3–13,394 pg/mL, p = 0.632)
(Fig. 4). An adjustment to the approximate mean age of 50
years was made across all groups (Yilmaz et al. 2017). The
comparison is shown in Fig. 4b. After age adjustment, the
Fig. 1 Correlation between CSF and serum NFL in 52 patients with
different manifestations of VZV CNS infection (r = 0.72, p < 0.001).
Subgroup analysis was made using ANCOVA. The interaction between
subgroup and CSF NFL was not significant, and therefore, parallel
regression lines were assumed. CSF cerebrospinal fluid, NFL
neurofilament light chain
Fig. 2 Serum NFL
concentrations in the patient
group with VZVCNS infection as
a whole (n = 56) compared with
HZ controls (a), and divided into
subgroups based on diagnosis,
compared with controls (b).
Median and IQR are shown. HZ
herpes zoster, NFL neurofilament




encephalitis patients still showed significantly higher levels of
CSF NFL compared with patients with meningitis (p = 0.016),
but not to those with Ramsay Hunt syndrome (p = 0.062).
Rash
To investigate if the presence of a rash affects serum NFL con-
centration, we divided the VZV CNS infection group into pa-
tients with or without rash. Twenty-eight out of the 56 patients
with VZV CNS infection (50%) that had been analysed for se-
rum NFL had a rash. These patients had a tendency towards
higher concentrations of serum NFL compared with those lack-
ing a rash (28 out of 56 patients) although not significant (median
36.8 pg/mL; IQR 16.1–156.7 versus 8.6 pg/mL; 6–78.7, p =
0.139) (Fig. 5). However, the concentrations of serum NFL in
the herpes zoster controls were significantly higher when com-
paring with the patients lacking a rash in the VZVCNS infection
group (p = 0.018). In addition, no significant difference was
shown when comparing the herpes zoster controls with the pa-
tients that had a rash in the VZV CNS infection group (57.3 pg/
mL; IQR 17.2–124.5 versus 36.8 pg/mL; 16.1–156.7, p =
0.715). Thus, based on these results, we cannot exclude an asso-
ciation between rash and higher serum NFL concentrations in
patients with VZV infection.
Viral load, albumin ratio and immunosuppression
There was no significant correlation between the amount of
CSF VZV DNA, i.e. viral load, and concentrations of NFL in
either CSF (r = 0.13, p = 0.33) or in serum (r = 0.22, p = 0.11)
in the patients with VZV CNS infection. Furthermore, multi-
ple comparison of viral load between the different patient
groups with VZV CNS infection showed significantly higher
viral load only when comparing the patients with encephalitis
and “other neurological symptoms” (p = 0.039) (see Table 1
for viral load in different groups).
To evaluate if the serum NFL concentrations were depending
on the degree of blood-brain barrier damage in the patients with
VZV CNS infections, the serum/CSF NFL ratios were analysed
for correlation with the albumin ratios. No correlation was found
when including all values (r = 0.11, p = 0.45). Yet, a scatter plot
indicated a possible influence of two outliers (Fig. 6), and after
exclusion of the outliers, a positive correlation was shown (r=
0.42, p = 0.004). However, further subgroup analysis showed
that there was a significant negative correlation in the meningitis
patients (r= − 0.48, p = 0.04). The CSF NFL concentrations and
albumin ratios correlated (r = 0.48, p < 0.001), whereas a less
strong but significant correlation was found between the serum
NFL concentrations and albumin ratios (r= 0.29, p= 0.04).
The influence of immunosuppression on serum NFL concen-
trations was also evaluated. Within the VZV CNS infection
group, the immunocompromised patients presented higher con-
centrations of serum NFL (median 156.2 pg/mL; IQR 41.8–
515.2 pg/mL) versus the immunocompetent patients (20.9 pg/
mL; 7.1–84.9 pg/mL) (p= 0.0039). In the herpes zoster control
group, the concentrations of serum NFL were not significantly
different between immunocompromised and immunocompetent
Table 2 p values for
group comparisons in the
analysis of covariance of
serum NFL with age as a
covariate (Fig. 3). The
comparison was
calculated at the
approximate mean age =
50
Group comparisons p value
Enc vs. HZ 0.850
Enc vs. ONS 0.137
Enc vs. RHS* 0.028
Enc vs. Men* < 0.001
Enc vs. HC* < 0.001
HZ vs. ONS 0.138
HZ vs. RHS* 0.023
HZ vs. Men* < 0.001
HZ vs. HC* < 0.001
ONS vs. RHS 0.691
ONS vs. Men* 0.021
ONS vs. HC* 0.010
RHS vs. Men* 0.032
RHS vs. HC* 0.013
Men vs. HC 0.773
Enc encephalitis, HC healthy controls, HZ
herpes zoster controls, Men meningitis,
NFL neurofilament light chain, ONS other
neurological symptoms, RHS Ramsay
Hunt syndrome
*Statistically significant
Fig. 3 Analysis of covariance of serum NFL with age as a covariate. The
dotted line represents the approximate mean age = 50 at which the group
comparisons were calculated. NFL neurofilament light chain
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patients (60.8 pg/mL; 44.8–155.2 pg/mL versus 35.2 pg/mL;
16.2–88.7 pg/mL, p = 0.319).
Discussion
This study is to our knowledge the first to examine serumNFL
concentrations in patients with VZV CNS infection. Our re-
sults indicate that analysis of serum NFL may be used instead
of analysis of CSF for estimation of neuronal injury in patients
with VZV CNS infection and possibly also in other viral CNS
infections. The finding of a strong correlation between serum
and CSF NFL is in agreement with recent studies including
patients with CNS injury in HIV infection (Gisslen et al.
2016), multiple sclerosis (Disanto et al. 2017; Piehl et al.
2018) and traumatic brain injury (Shahim et al. 2016). In ad-
dition, serum NFL seems to correlate well with CSF NFL
within each clinical subgroup, but the ratio between serum
and CSF NFL varied depending on the clinical manifestation
(Fig. 1). The encephalitis patients showed higher levels of
serum/CSF NFL ratio compared with the meningitis patients,
and therefore, comparison of serum NFL levels between sub-
groups should be made with caution. Moreover, this differ-
ence raised the question whether the degree of blood-brain
barrier damage influenced the serum/CSF NFL ratio.
Both CSF and serum NFL concentrations correlated with
increasing blood-brain barrier damage measured by the CSF/
serum albumin ratio, as previously shown in studies of dementias
and in CNS injury in HIV (Gisslen et al. 2016; Skillback et al.
2017). One may assume that in CNS infections, increasing
blood-brain barrier damage would cause increased leakage of
NFL from CSF to serum, leading to an increasing serum/CSF
NFL ratio in conjunction with increasing albumin ratio.
However, our results were contradictory, as a positive correlation
was found when including all patients except outliers, but a neg-
ative correlationwas seen in the subgroup ofmeningitis. A recent
study by Kalm et al. (Kalm et al. 2017) found no influence of
blood-brain barrier damage on serumNFL levels. Another theory
is that the degree of blood-brain barrier damage is a general
marker of disease severity and therefore correlates with the con-
centrations of NFL in both serum and CSF but not with serum/
CSF NFL ratio. In severe CNS disease, there is probably an
increased risk of both blood-brain barrier damage and consider-
able injury of neurons (Anesten et al. 2016).
The encephalitis patients had the highest serum NFL concen-
trations when compared with the patients with meningitis and
Fig. 4 CSF NFL concentrations
in 57 patients with VZV CNS
infection (a), and adjusted to age
(b). The approximate mean
age of 50 was used for age
adjustment. Median and IQR are
shown. CSF cerebrospinal fluid,
NFL neurofilament light chain,
RHS Ramsay Hunt syndrome
Fig. 5 Serum NFL concentrations in the patients with VZV CNS
infection, divided depending on presence of rash or not, and compared
with HZ controls. Median and IQR are shown. HZ herpes zoster, NFL
neurofilament light chain, ns not significant, VZV varicella-zoster virus
Fig. 6 Correlation between NFL ratio (serum NFL/CSF NFL) and
albumin ratio (r = 0.42, p = 0.004). Two outliers were excluded prior to
correlation analysis. Subgroup analysis showed that there was a
significant negative correlation in the meningitis patients (r = − 0.48,
p = 0.04). NFL neurofilament light chain
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Ramsay Hunt syndrome. Encephalitis is considered the most
severe manifestation of VZVCNS infection. Indeed, higher con-
centrations of serum NFL have been correlated to increased dis-
ease activity in several neurological diseases such as multiple
sclerosis (Disanto et al. 2017), amyotrophic lateral sclerosis (Lu
et al. 2015) and CNS injury in HIV infection (Gisslen et al.
2016). However, unexpectedly, the herpes zoster control patients
without CNS manifestations had very high concentrations of
serum NFL, comparable with the levels seen in the encephalitis
patients. This leads to the assumption that peripheral nerve dam-
age increases serum NFL levels in patients with rash due to
VZV. Peripheral nerves produce NFL (Trojanowski et al.
1986) and can be damaged due to herpes zoster (Schmidbauer
et al. 1992). Furthermore, serum NFL concentrations are in-
creased in inherited peripheral neuropathies (Sandelius et al.
2018) and Guillain-Barré syndrome (Gaiottino et al. 2013).
Interestingly, the latter study also showed increased CSF NFL
levels, supposedly related to peripheral nerve degradation. In
older autopsy studies of patients with herpes zoster
(Schmidbauer et al. 1992), it seems like the neuronal damage
also include nerve roots situated in the spinal canal, which may
yield increased CSF NFL concentrations also in herpes zoster
patients without clinical symptoms of CNS disease. Additional
studies that include CSF samples from herpes zoster patients
would be of interest to further elucidate this matter.
In conjunction with high levels of serum NFL, the patients
with encephalitis also demonstrated higher concentrations of
CSF NFL compared with the patients with meningitis and
Ramsay Hunt syndrome. After age adjustment, this difference
remained in comparison with that of the meningitis patients.
Encephalitis patients have been reported to have high concentra-
tions of CSFNFL also in a previous study (Grahn et al. 2013). In
that study, no significant differences in CSF NFL concentrations
were found between encephalitis and meningitis patients, but the
patient groups were smaller than in the present study. In enceph-
alitis, the infection reaches into the brain, with a large number of
neurons, whereas inmeningitis, it is mainly themeninges that are
involved, with far less neurons. Therefore, higher concentrations
of NFL in CSF and serum in patients with encephalitis seem
logic, as they reflect the number of neurons that are affected. In
addition, it is reasonable to assume different pathogenesis be-
tween these two CNS manifestations, as supported by recent
findings of different chemokine response (Lind et al. 2019) and
higher viral diversity in encephalitis versus meningitis caused by
VZV (Depledge et al. 2018).
The influence of immunosuppression on levels of NFL is
unclear. In our material, the immunocompromised patients in
the VZV CNS infection group showed higher levels of serum
NFL than immunocompetent patients. In contrast, this was not
shown in the herpes zoster control group. As the inflammatory
response differ between the CNS and the peripheral nervous
system in patients with CNS infections caused by herpes sim-
plex virus and VZV (Lind et al. 2019; Lind et al. 2017), we
can only speculate that immunosuppression may affect the
inflammatory response in different ways in the central and
peripheral nervous systems in these patients.
Finally, as the serum NFL assay means much less harm for
the patient by avoiding a lumbar puncture, this assay can be a
convenient tool for assessing the prognosis and for monitoring
of disease in patients with VZV CNS infection and probably
also in other viral CNS infections. However, longitudinal
studies are warranted for evaluation of this purpose.
In conclusion, our findings demonstrate a strong correla-
tion between serum and CSF NFL, suggesting that analysis of
serum NFL could be used instead of CSF NFL for evaluation
of neuronal injury in VZV CNS infection. However, high
levels of serum NFL were also seen in patients with herpes
zoster without signs of CNS involvement, indicating an influ-
ence of peripheral nerve damage on serum NFL, which could
complicate the interpretation. In addition, we found signifi-
cantly higher concentrations of NFL in both serum and CSF
in patients with encephalitis compared with that of meningitis
which strengthens the argument of using the serumNFL assay
in prognostic purpose in VZV CNS infections.
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